Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript
Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.44.
Kymera Therapeutics Inc. (KYMR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,995,928 | $152,656,327 | +27% | 1.73% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,161,801 | $131,419,453 | +9% | 3.28% |
| 3. | VenBio Select Advisor Kurt Von Emster | 3,775,000 | $96,111,500 | -3% | 1.32% |
| 4. | Redmile Group Jeremy Green | 1,823,956 | $46,437,920 | -3% | 1.66% |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,522,238 | $38,756,179 | +2% | 0.95% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.07 | 10,106 | Director, Other | 294,632 | 2023-11-03 | Filing | |
| $14.07 | 83,708 | Director, Other | 2,104,075 | 2023-11-03 | Filing | |
| $14.07 | 103,885 | Director, Other | 2,656,191 | 2023-11-03 | Filing | |
| $11.64 | 26,772 | Director, Other | 284,526 | 2023-11-02 | Filing | |
| $11.64 | 132,016 | Director, Other | 2,020,367 | 2023-11-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $41.23 | 329 | 806,697 | 2024-03-15 | Filing | ||
| $40.62 | 10,411 | 807,026 | 2024-03-15 | Filing | ||
| $39.31 | 1,714 | 817,437 | 2024-03-15 | Filing | ||
| $41.23 | 1,593 | 4,570,665 | 2024-03-15 | Filing | ||
| $40.62 | 49,591 | 4,572,258 | 2024-03-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,858,262 | $149,151,351 | 17.76% | |
| 2. | 4,815,558 | $122,604,107 | 0.02% | |
| 3. | 3,997,564 | $101,777,980 | 0% | |
| 4. | 3,566,611 | $90,805,915 | 0% | |
| 5. | 1,894,279 | $48,228,343 | 0% |
News See All
12 Most Promising Cancer Stocks According to Analysts
In this piece, we will take a look at the 12 most promising cancer stocks according to analysts.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter 2023 Results Call. [Operator Instructions]. Please note that this event is being recorded.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2023 Earnings Call Transcript
Bruce Jacobs: Good morning everyone and welcome to the Kymera Therapeutics quarterly conference call.
12 Stocks with Biggest Upside Potential According to Analysts
In this article, we will take a look at the 12 stocks with biggest upside potential according to analysts.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Kymera Therapeutics First Quarter 2023 Earnings Conference Call [Operator Instructions]. Please note that this event is being recorded today.
12 Small-Cap Stocks With Insider Buying
Insider buying refers to a company's officers, directors, or major shareholders purchasing shares of their own company's stock.
15 Most Shorted Stocks Right Now on Wall Street
Short selling is a way for traders to make money by betting that the price of a stock will go down.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2022 Earnings Call Transcript
Operator: Hello, and welcome to the Kymera Therapeutics Fourth Quarter 2022 Earnings Conference Call. Please note, this event is being recorded.
Hedge Fund and Insider Trading News: Dan Loeb, Ray Dalio, Julian Robertson, Argonaut Capital, Three Arrows Capital, AlphaNorth Asset Management, Ecolab Inc. (ECL), CASI Pharmaceuticals Inc (CASI), and More
Hedge fund manager Barry Norris said the cinema chain had used “too much financial debt” to do its deals in what is “a sunset industry”.